Article

Overcoming ibrutinib resistance by targeting phosphatidylinositol-3-kinase signaling in diffuse large B-cell lymphoma

2019-01-28

Abstract excerpt

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma; 40% of patients relapse following a complete response or are refractory to therapy. The activated subtype of diffuse large B-cell lymphoma relies upon B-cell receptor signaling for survival; this signaling can be modulated by the activity of Bruton’s tyrosine kinase. Targeting that kinase with its inhibitor ibrutinib provides a poten...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: be999ac6-b6ef-5172-be94-d552546fa220
DOI: 10.1101/523761

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Overcoming ibrutinib resistance by targeting phosphatidylinositol-3-kinase signaling in diffuse large B-cell lymphomaDOI 10.1101/523761Read

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.Semantic proximity Read

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.Semantic proximity Read

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphomaSemantic proximity Read

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.Semantic proximity Read

miR-28 plus ibrutinib as a novel combination therapy for Diffuse Large B Cell LymphomaSemantic proximity Read

Targeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCLSemantic proximity Read

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell MalignanciesSemantic proximity Read

Regulation of B Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell LymphomasSemantic proximity Read

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCLSemantic proximity Read

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical ModelsSemantic proximity Read

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasSemantic proximity Read